We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mallinckrodt (MNK) Commences Phase III Study of StrataGraft
Read MoreHide Full Article
Mallinckrodt plc has enrolled the first patient in phase III study, assessing StrataGraft regenerative skin tissue for promoting autologous skin regeneration in patients with thermal burns.
The company’s share price decreased 19.7% year to date compared with the Zacks classified Medical – Generics Drugs industry’s decline of 6.7%.
The phase III study will include patients with 3-49% of complex skin defects on their total body surface area due to thermal burns with dermal elements intact. Excision and autografting are clinically indicated to treat the burns.
The company is working with the United States Biomedical Advanced Research and Development Authority (BARDA), supporting the StrataGraft development.
We remind investors that Mallinckrodt added StrataGraft to its portfolio through acquisition of Stratatech Corporation, a privately held regenerative medicine company, focused on developing unique, proprietary skin substitute products in August last year.
The FDA had granted an orphan product status to StrataGraft in 2012. Upon a potential approval, StrataGraft could be the first biological "off-the-shelf" skin substitute product for treatment of severe burns.
Every year, approximately 10,000 patients in the U.S. are hospitalized for the treatment of severe burns and the market for skin graft products used in this application is estimated to be approximately $300 million in the country.
Mallinckrodt carries a Zacks Rank #3 (Hold). Some better ranked stocks in health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Aeglea BioTherapeutics . While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Aeglea carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the ast 60 days. The company posted positive earnings surprises in all four trailing quarters, with an average beat of 233.69%. The share price of the company increased 12.2% year to date.
MEI Pharma’s estimates reduced from loss per share of 1 cent to gain per share of the same for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with average beat of 66.56%. The share price of the company increased 37.5% year to date.
Aeglea’s loss per share estimates narrowed from $3.64 to $2.48 for 2017 over last 60 days. The company posted positive earnings surprises in three of four trailing quarters, with average beat of 20.75%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy... Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early.Download Report with 3 Top Tech Stocks >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Mallinckrodt (MNK) Commences Phase III Study of StrataGraft
Mallinckrodt plc has enrolled the first patient in phase III study, assessing StrataGraft regenerative skin tissue for promoting autologous skin regeneration in patients with thermal burns.
The company’s share price decreased 19.7% year to date compared with the Zacks classified Medical – Generics Drugs industry’s decline of 6.7%.
The phase III study will include patients with 3-49% of complex skin defects on their total body surface area due to thermal burns with dermal elements intact. Excision and autografting are clinically indicated to treat the burns.
The company is working with the United States Biomedical Advanced Research and Development Authority (BARDA), supporting the StrataGraft development.
We remind investors that Mallinckrodt added StrataGraft to its portfolio through acquisition of Stratatech Corporation, a privately held regenerative medicine company, focused on developing unique, proprietary skin substitute products in August last year.
The FDA had granted an orphan product status to StrataGraft in 2012. Upon a potential approval, StrataGraft could be the first biological "off-the-shelf" skin substitute product for treatment of severe burns.
Every year, approximately 10,000 patients in the U.S. are hospitalized for the treatment of severe burns and the market for skin graft products used in this application is estimated to be approximately $300 million in the country.
Mallinckrodt PLC Price
Mallinckrodt PLC Price | Mallinckrodt PLC Quote
Zacks Rank and Stocks to Consider
Mallinckrodt carries a Zacks Rank #3 (Hold). Some better ranked stocks in health care sector include VIVUS, Inc. , MEI Pharma, Inc. (MEIP - Free Report) and Aeglea BioTherapeutics . While VIVUS and MEI Pharma sport a Zacks Rank #1 (Strong Buy), Aeglea carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates narrowed from 502 cents to 39 cents for 2017 over the ast 60 days. The company posted positive earnings surprises in all four trailing quarters, with an average beat of 233.69%. The share price of the company increased 12.2% year to date.
MEI Pharma’s estimates reduced from loss per share of 1 cent to gain per share of the same for 2017, over the last 60 days. The company posted positive earnings surprises in three of the four trailing quarters, with average beat of 66.56%. The share price of the company increased 37.5% year to date.
Aeglea’s loss per share estimates narrowed from $3.64 to $2.48 for 2017 over last 60 days. The company posted positive earnings surprises in three of four trailing quarters, with average beat of 20.75%.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy... Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>